

**Wanbury Limited**

Regd. Office : BSEL Tech Park, B-wing
10th Floor, Sector-30 A,
Opp. Vashi Railway Station,
Vashi Navi Mumbai 400 703
Maharashtra, INDIA
Tel. : +91-22-6794 2222
+91-22-7196 3222
CIN L51900MH1988PLC048455
Email : info@wanbury.com
Website : www.wanbury.com

6th March, 2025

To BSE Limited PJ. Towers, Dalal Street , Mumbai - 400 001. Script Code: 524212	To National Stock Exchange of India Ltd, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051. Script Code: WANBURY
---	--

Sub.: Disclosure under Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Ref: Refinancing of Outstanding Debentures

Dear Sir/Madam,

Pursuant to Regulation 30 of SEBI Listing Regulations, please find enclosed herewith the Press Release on Refinancing of Outstanding Debentures.

This is for your information and record.

Thanking you.

Yours truly,
For Wanbury Limited



Jitendra J. Gandhi
Company Secretary



Wanbury Limited Achieves Significant Interest Cost Savings Through Refinancing of Outstanding Debentures

6th March, 2025, MUMBAI: Wanbury Limited ("Wanbury"), a pharmaceutical company with a presence in the global API market and domestic branded formulations, announces a major milestone in its financial strategy with the successful refinancing of a portion of its outstanding Non-Convertible Debentures ("NCDs").

Wanbury repurchased the entire issue of 21% Secured Non-Convertible Debentures placed initially in July 2023 on private placement basis amounting to Rs.95 crores from NEO AIF and associates. The Wanbury facilitates this transaction through refinancing of debt of Rs. 175 crore of Tranche I from Emerging India Credit Opportunities Fund II (an associate of Investec Capital Services (India) Pvt. Ltd.) at a substantial reduce interest rate of 12.5 % p.a. upto Rs.150 Crore of existing outstanding Debt (i.e. NEO AIF & Associates amounting to Rs.90 crores and other Lenders amounting to Rs.60 Crores) and balance towards working capital & capex for the growth of the Company. The Repayment of the said facility is in 5 years with average life up to 3.25 years having a moratorium period of 9 months.

Mr. Mohan Rayana, Whole-time Director of Wanbury Ltd., said, "We're pleased to announce the successful refinancing, underscoring our commitment to financial stability and growth. This strategic move reflects our dedication to optimizing shareholder returns and strengthening our financial foundation. We're glad to announce the successful refinancing with Emerging India Credit Opportunities Fund II (an associate of Investec Capital Services (India) Pvt. Ltd.), resulting in significant savings in Interest cost. This reduction in interest costs is a testament to our consistent performance and overall stability in revenue generation. This transaction serves to strengthen the Company's strategic approach. Last but not least, I would like to extend my gratitude to our investors and team for their unwavering support and dedication throughout this process."

About Wanbury Limited:

Established in 1988, listed on the National Stock Exchange of India Ltd (Code: WANBURY) and BSE Ltd (Code: 524212). The company has a strong presence in API global market and domestic branded Formulation with its API being exported to over 50 countries and has Pan-India Formulation presence. The company has two USFDA & EUGMP approved facilities at Tanuku (Andhra Pradesh) and Patalganga (Maharashtra).

The API product portfolio includes: Metformin, Sertraline, Tramadol, Diphenhydramine, Mefenamic acid, Paroxetine and various other products in pipeline. The company's clients include some of the leading global generic players.

In formulations, the company has a wide presence across major therapeutic categories like, cough and cold solutions, gynaecology, orthopaedics, nutraceuticals, gastro intestinal, anti-inflammatory, & analgesics.





For more details on Wanbury Ltd.: <https://www.wanbury.com/>

For further information please contact:

Jitendra J. Gandhi
Company Secretary
Wanbury Limited
BSEL Techpark, B' Wing, 10th Floor,
Sector 30-A, Opp. Vashi Railway Station,
Vashi, Navi Mumbai - 400 703, India.
Tel: +91-22-6794 2222
Email: jitendra.gandhi@wanbury.com

Hanishi Shah / Anand Venugopal
Adfactors PR
Oasis Complex, Kamala Mills Compound,
City Hall, Pandurang Budhkar Marg, Lower
Parel West, Mumbai - 400 021.
Tel: +91 9619059339 / +91 7021852071
Email: hanishi.shah@adfactorspr.com
anand.venugopal@adfactorspr.com

Disclaimer:

This press release which has been prepared by Wanbury Limited is solely for information purposes and do not constitute any offer, recommendation, or invitation to purchase or subscribe for any securities and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever.

